Skip to main content
Premium Trial:

Request an Annual Quote

Bioneer Wins Grant to Develop RNAi Drug for Dengue Fever

Premium

NEW YORK (GenomeWeb) – South Korea's Bioneer announced that it has received a two-year, $1.3 million grant from the Korea Health Industry Development Institute to develop an siRNA-based therapy for dengue fever.

The therapeutic is based on Bioneer's so-called self-assembled micelle inhibitory RNA, or SAMiRNA, nanoparticle technology, and incorporates siRNAs targeting the dengue virus genome.

According to the company, it has received $500,000 of the award to conduct in vivo testing of its drug in a mouse model of dengue virus infection, which will be run in collaboration with the La Jolla Institute for Allergy and Immunology.

Upon successful completion of this first stage of the project, Bioneer is eligible to receive the remaining $800,000 in 2015.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.